Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences

Rhea-AI Summary

Satsuma Pharmaceuticals (Nasdaq: STSA) announced its participation in two upcoming virtual healthcare conferences. The Credit Suisse 29th Annual Healthcare Conference will take place from November 9-12, 2020, featuring one-on-one meetings with management. Following this, Satsuma will attend the Stifel 2020 Virtual Healthcare Conference from November 16-18, 2020, also involving one-on-one management meetings. Satsuma focuses on developing STS101, a novel migraine treatment utilizing a proprietary nasal delivery device for rapid self-administration.

News Market Reaction – STSA

+3.05%

+3.05% Session move

In the trading session that priced this news, STSA gained 3.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Credit Suisse - 29^th Annual Healthcare Conference -
November 9^th -12^th

- Stifel 2020 Virtual Healthcare Conference -
November 16^th -18^th

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the following conferences in the month of November. Please see additional details below:

Credit Suisse 29th Annual Healthcare Conference
Dates:	Monday – Thursday, November 9th-12th 2020
Format:	One-on-One meetings with Satsuma Management
Location:	Virtual Meetings
Stifel 2020 Virtual Healthcare Conference
Date:	Monday – Wednesday, November 16th-18th 2020
Format:	One-on-One meetings with Satsuma Management
Location:	Virtual Meetings

About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS:         

Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com

FAQ

What conferences is Satsuma Pharmaceuticals participating in November 2020?

Satsuma Pharmaceuticals will participate in the Credit Suisse 29th Annual Healthcare Conference from November 9-12 and the Stifel 2020 Virtual Healthcare Conference from November 16-18.

What is STS101 developed by Satsuma Pharmaceuticals?

STS101 is a novel therapeutic product designed for the acute treatment of migraines, featuring a proprietary nasal delivery device for easy self-administration.

What is the format of Satsuma's presentations at the conferences?

The format includes one-on-one meetings with Satsuma management during both conferences.

Where is Satsuma Pharmaceuticals headquartered?

Satsuma Pharmaceuticals is headquartered in South San Francisco, California.